Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01252875 : Treat Stroke to Target
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- • Recent (less than 3 months) ischemic stroke

- As soon as possible after the event, once the neurologic deficit is stabilized
(investigator judgment)

- These ischemic strokes include TIA with ischemic lesion documented by CT or MRI

• Or recent TIA (less than 15 days)

- without documentation of ischemic lesion on CT/MR imaging

- Must be limb weakness or aphasia lasting more than 10 min

• And documented atherosclerotic stenosis

- In carotid artery (investigator judgment) (based on the results of Duplex echography,
CTA, MRA or X ray- angiography)

- Or in the aortic arch (investigator judgment) (based on TEE or CTA)

- Or in other brain artery: vertebral, basilar or other intracranial artery (based on

- Or in coronary arteries (past history of acute coronary syndrome, coronary
revascularization or positive coronary angiography)

• And

- Statin treatment is indicated, following ANSM guidelines (French drug agency)

- age >18 years

- rankin score ? 4

- patient or a legal representative signs consent

- Patient is affiliated to social security system

Exclusion Criteria:

- • Ischemic stroke/TIA du to

- arterial dissection (investigator judgment)

- Cardiac source of embolism (e.g., mitral stenosis, endomyocardial fibrosis) without
documented atherosclerotic stenosis : a patient with atrial fibrillation or a past
history of recent myocardial infarction or calcified aortic stenosis can be
randomized if he otherwise fulfils inclusion criteria

• Symptomatic hemorrhagic stroke

- Presence of microbleeds on gradient echo imaging (T2*) is not an exclusion criteria.

- Hemorrhagic transformation of an ischemic stroke is not an exclusion criteria

- Uncontrolled hypertension (investigator judgment)

- LDL-C <100 mg/dL or patients for whom treatment intensification is impossible

- F/U impossible or bad observance anticipated.

- Co-morbid condition that may interfere with the F/U or with the evaluation of
primary endpoint

- Participation to another clinical trial
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557